Ertumaxomab

Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer.

Ertumaxomab
Monoclonal antibody
TypeTrifunctional antibody
SourceRat/mouse hybrid
TargetHER2/neu, CD3
Clinical data
Trade namesRexomun
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
 NY (what is this?)  (verify)

It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells.[1]

Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans.[2] (So they could concentrate on their other product catumaxomab (trade name Removab).[3]:35)

References



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.